Zepbound is a dual-activating medication that combines glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like ...

Next-gen obesity biotech Metsera has filed to debut on the public markets, proposing an IPO nine months after emerging. | ...

Compounding pharmacies make their own versions of weight loss drugs at a fraction of the price but there are some drawbacks.

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions ...

The changes reflect “a cultural shift” around obesity medications, said Diana Zuckerman, president of the nonprofit National ...

There is a photo that exemplifies the paradox of Robert F. Kennedy Jr.’s nomination as secretary of the Health and Human ...

The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with obesity.

Key Takeaways Eli Lilly's Zepbound can be covered by Medicare Part D plans after the FDA approved the drug as a treatment for ...

Top stocks for 2025 are from the companies that have proven growth track records and strong outlooks, with more potential ...

Dignity Health January marks Healthy Weight Awareness Month, and with the new year, many are setting health and weight loss ...

With three meds approved for weight management and several on the way, these may make a dent in the obesity epidemic.

Political and economic uncertainty hangs over the industry, while major bets on metabolic and immune disease drug research ...